Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 82 matching trials from the live ClinicalTrials.gov search.
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years to 64 Years
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

NCT01243060
Conditions
Healthy Volunteers
Interventions
Almorexant, Zolpidem 10mg, Placebo
Drug
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
19 Years to 39 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Sedative-Anxiolytic Effects on Simulated Driving Performance

NCT03297944
Conditions
Psychomotor Impairment
Interventions
Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC), Zolpidem 10mg (ZOL/PLC), Placebo (PLC/PLC), Alprazolam 1mg (PLC/ALC)
Drug
Lead sponsor
Marion Coe
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 4 Interventional Results available

CBT-I or Zolpidem/Trazodone for Insomnia

NCT04468776
Conditions
Chronic Insomnia
Interventions
Zolpidem, Internet Cognitive Behavioral Therapy for Insomnia (CBT-I), Trazodone
Drug · Behavioral
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Tucson, Arizona • Columbia, Missouri + 4 more
Conditions
Sleep, Memory
Interventions
zaleplon, zolpidem extended release, bedtime placebo, middle of the night placebo
Drug
Lead sponsor
St. Luke's Hospital, Chesterfield, Missouri
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chesterfield, Missouri
Completed Not applicable Interventional Results available

Sequenced Therapies for Comorbid and Primary Insomnias

NCT01651442
Conditions
Insomnia Comorbid to Psychiatric Disorder, Primary Insomnia
Interventions
Behavioral Insomnia Therapy, Zolpidem, Trazodone, Cognitive Therapy
Behavioral · Drug
Lead sponsor
Jack Edinger, PhD
Other
Eligibility
21 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Conditions
Parental/Caregiver Anxiety, Child's Anxiety
Interventions
zolpidem, Midazolam
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
2 Years to 9 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Primary Insomnia
Interventions
Adipiplon, Placebo, Ambien CR
Drug
Lead sponsor
Neurogen Corporation
Industry
Eligibility
21 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Pembroke Pines, Florida • South Miami, Florida • Atlanta, Georgia + 6 more
Conditions
Spine Fusion, Lumbar Spine Degeneration, Pain, Postoperative, Lumbar Spine Spondylosis
Interventions
Zolpidem Tartrate 10 mg, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Insomnia
Interventions
zolpidem tartrate
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Insomnia
Interventions
Ramelteon, zolpidem and placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
6
States / cities
Costa Mesa, California • San Diego, California • Miami, Florida + 3 more
Conditions
Insomnia, Insomnia Chronic
Interventions
Zolpidem tartrate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Role of Sleep in the Treatment of Cannabis Use Disorders

NCT01685073
Conditions
Drug Addiction
Interventions
Zolpidem extended-release, MET/CBT
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Insomnia, Sleep Disorder
Interventions
Zolpidem
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
11
States / cities
Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Lavender vs Zolpidem Sleep Quality During Diagnostic PSG

NCT04102345
Conditions
Sleep
Interventions
Lavender Aromatherapy, Zolpidem
Other · Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Maplewood, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions

NCT00779051
Conditions
Healthy
Interventions
Zolpidem 10mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Completed Phase 2Phase 3 Interventional Results available

Two Contrasting Interventions for Sleep Management

NCT01804036
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
Zolpidem, Mind-Body Bridging
Drug · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
17 Years to 40 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Colorado Springs, Colorado • Salt Lake City, Utah
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Conditions
Progressive Supranuclear Palsy(PSP), Insomnia
Interventions
Suvorexant, Zolpidem, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Autism, Autism Spectrum Disorder
Interventions
Zolpidem, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Conditions
Healthy Recreational Drug Users
Interventions
ACT-541468, Suvorexant, Zolpidem, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Completed No phase listed Observational Accepts healthy volunteers

Safety and Efficacy of Chronic Hypnotic Use

NCT01006525
Conditions
Primary Insomnia
Interventions
zolpidem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
21 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Detroit, Michigan